Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 20:28:100534.
doi: 10.1016/j.ijcha.2020.100534. eCollection 2020 Jun.

Pharmacological inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut reduces atrial fibrillation susceptibility in obese spontaneously hypertensive rats

Benedikt Linz  1   2 , Mathias Hohl  1 , Ricardo Mishima  3 , Arnela Saljic  2 , Dennis H Lau  3 , Thomas Jespersen  2 , Ulrich Schotten  4 , Prashanthan Sanders  3 , Dominik Linz  1   3   4
Affiliations

Pharmacological inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut reduces atrial fibrillation susceptibility in obese spontaneously hypertensive rats

Benedikt Linz et al. Int J Cardiol Heart Vasc. .

Abstract

Background: Increased sodium uptake has been shown to contribute to hypertension and cardiac end-organ damage. The sodium-proton-exchanger subtype 3 (NHE3) is an important mediator of intestinal sodium absorption. Whether a reduction in intestinal sodium absorption can prevent the development of an atrial arrhythmogenic substrate in hypertension is unknown.

Methods: Eight-week-old obese spontaneously hypertensive rats (SHR-ob) were treated for six weeks with the gut-specific NHE3-inhibitor SAR (1-(β-D-glucopyranosyl)-3-{3-[(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroiso-chinolin-4-yl]phenyl}urea, 1 mg/kg/d in chow, SHR-ob SAR, n = 7) and compared to aged-matched placebo-treated SHR-ob (SHR-ob PLAC, n = 8). Cardiac magnetic resonance imaging was performed at the end of the treatment period to assess atrial emptying function. Afterwards, local conduction disturbances and inducible atrial fibrillation (AF) duration were determined and histological analysis to quantify atrial fibrosis amount were performed.

Results: Inhibition of intestinal NHE3 by SAR increased fecal sodium excretion, resulted in marked changes in feces electrolyte concentrations and water content, reduced blood pressure and preserved atrial emptying function (active total percent emptying: SHR-ob SAR: 0.47 ± 0.05% vs. SHR-ob PLAC: 0.38 ± 0.007, p < 0.0001). Atrial fibrosis content was lower (21.4 ± 2.5% vs. 36.7 ± 1.2%, p < 0.0001) and areas of slow conduction were smaller (2.5 ± 0.09% vs. 5.3 ± 0.2%, p < 0.0001) in SHR-ob SAR compared to SHR-ob PLAC. Left atrial burst stimulation resulted in shorter inducible AF-durations in SHR-ob SAR compared to SHR-ob PLAC.

Conclusions: Reduction of intestinal sodium absorption and subsequent changes in feces milieu by pharmacological NHE3 inhibition in the gut preserved atrial emptying function and reduced AF susceptibility. Whether pharmacological NHE3 inhibition in the gut prevents AF in humans warrants further study.

Keywords: Atrial fibrillation; Intestinal sodium absorption; Salt; Sodium-proton-exchanger Subtype 3 (NHE 3).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Structural remodeling of the left atrium. A) Representative picture of Picro-Sirius red stained left atria. B) Quantification of total atrial tissue fibrosis by Picro-Sirius red staining. C) Myocyte-myocyte distances within bundles as a measure of enhanced extracellular LA matrix formation and D) atrial myocyte diameter. Male obese spontaneously hypertensive rats (SHR-ob). Placebo (PLAC). NHE3-inhibitor SAR (SAR). SHR-ob PLAC (n = 8) and SHR-ob SAR (n = 7). All values represented as mean ± SEM. For statistical analysis an unpaired student’s t-test was performed.
Fig. 2
Fig. 2
Quantification of global left atrial (LA) emptying function. Left atrial (LA) emptying function was assessed by magnetic resonance imaging (MRI) in SHR-ob PLAC (n = 8) and SHR-ob SAR (n = 7) rats. Global LA function was assessed by determination of A) maximal LA volume index, B) total percent emptying, C) active percent emptying and D) passive percent emptying. Male obese spontaneously hypertensive rats (SHR-ob). E) Representative MRI images of 10 equal phases throughout the cardiac cycle at the level of the aortic valve are presented. Placebo (PLAC). NHE3-inhibitor SAR (SAR). All values represented as mean ± SEM. For statistical analysis an unpaired student’s t-test was performed.
Fig. 3
Fig. 3
Left atrial electrophysiological analysis and duration of burst-induced atrial fibrillation. Quantification of A) total atrial activation time and B) areas of slow conduction. C) Duration of inducible episodes of atrial fibrillation (AF). Male obese spontaneously hypertensive rats (SHR-ob). Placebo (PLAC). NHE3-inhibitor SAR (SAR). SHR-ob PLAC (n = 8) and SHR-ob SAR (n = 7). All values represented as mean ± SEM. For statistical analysis an unpaired student’s t-test was performed.
See this image and copyright information in PMC

References

    1. Mente A., O'Donnell M., Rangarajan S., McQueen M., Dagenais G., Wielgosz A., Lear S., Ah S.T.L., Wei L., Diaz R., Avezum A., Lopez-Jaramillo P., Lanas F., Mony P., Szuba A., Iqbal R., Yusuf R., Mohammadifard N., Khatib R., Yusoff K., Ismail N., Gulec S., Rosengren A., Yusufali A., Kruger L., Tsolekile L.P., Chifamba J., Dans A., Alhabib K.F., Yeates K., Teo K., Yusuf S. Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. Lancet. 2018;392(10146):496–506. - PubMed
    1. O'Donnell M., Mente A., Rangarajan S., McQueen M.J., Wang X., Liu L., Yan H., Lee S.F., Mony P., Devanath A., Rosengren A., Lopez-Jaramillo P., Diaz R., Avezum A., Lanas F., Yusoff K., Iqbal R., Ilow R., Mohammadifard N., Gulec S., Yusufali A.H., Kruger L., Yusuf R., Chifamba J., Kabali C., Dagenais G., Lear S.A., Teo K., Yusuf S., Investigators P. Urinary sodium and potassium excretion, mortality, and cardiovascular events. New England J. Med. 2014;371(7):612–623. - PubMed
    1. Nishida C., Uauy R., Kumanyika S., Shetty P. The joint WHO/FAO expert consultation on diet, nutrition and the prevention of chronic diseases: process, product and policy implications. Public Health Nutr. 2004;7(1A):245–250. - PubMed
    1. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S., Falk V., Gonzalez-Juanatey J.R., Harjola V.P., Jankowska E.A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J.T., Pieske B., Riley J.P., Rosano G.M.C., Ruilope L.M., Ruschitzka F., Rutten F.H., van der Meer P., E.S.C.S.D. Group 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016;37(27):2129–2200. - PubMed
    1. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M., Clement D.L., Coca A., de Simone G., Dominiczak A., Kahan T., Mahfoud F., Redon J., Ruilope L., Zanchetti A., Kerins M., Kjeldsen S.E., Kreutz R., Laurent S., Lip G.Y.H., McManus R., Narkiewicz K., Ruschitzka F., Schmieder R.E., Shlyakhto E., Tsioufis C., Aboyans V., Desormais I., E.S.C.S.D. Group 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart. J. 2018:71–159. doi: 10.5603/KP.2019.0018. - DOI

LinkOut - more resources